newsfilter
← Latest News
GlobeNewswire·

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

  • Faruqi & Faruqi, LLP is investigating potential securities law violations against Jasper Therapeutics, Inc. (NASDAQ: JSPR).
  • Investors who purchased Jasper securities between November 30, 2023, and July 3, 2025, are encouraged to contact partner Josh Wilson to discuss legal rights.
  • The complaint alleges Jasper failed to disclose that third-party manufacturers did not comply with cGMP regulations, risking confounded clinical study results.
  • Allegations state this manufacturing failure increased the likelihood of disruptive cost-reduction measures & overstated the Company's financial & clinical prospects.
  • On July 7, 2025, Jasper reported BEACON Study results were confounded by a defective drug lot affecting 10 of 13 patients.
  • Jasper halted the ETESIAN study & paused asthma development to focus resources on CSU development for briquilimab.
  • The Company also halted SCID development & announced cost-cutting measures & potential restructuring despite prior claims of a strong balance sheet.
  • Following the July 7 announcement, Jasper's stock price fell $3.73 per share (55.1%) to close at $3.04.
  • Investors must seek the role of lead plaintiff by the November 18, 2025, deadline.
  • The firm invites whistleblowers, former employees, shareholders, & others with information regarding Jasper's conduct to contact them.
  • Additional details are available at www.faruqilaw.com/JSPR or by calling 877-247-4292.